Cervical cancer remains a significant health burden globally, and the development of cervical cancer chemoresistance often leads to treatment failure. Consequently, researchers are now looking toward advanced nanotechnology to overcome these hurdles. Specifically, a new study introduces Bi-A@SR nanoparticles, which offer a multi-pronged strategy to enhance therapeutic outcomes.

Innovative Nanoplatform for Reversing Cervical Cancer Chemoresistance

Firstly, the Bi-A@SR nanoplatform utilizes a bismuth selenide core. Furthermore, it is decorated with cyclic RGD (cRGD) peptides for precise tumor targeting. In addition, the system co-loads the chemotherapeutic agent SN38 and the photothermal dye IR820. Consequently, when researchers apply 808 nm near-infrared (NIR) light, the platform triggers therapeutic effects. Specifically, the photothermal effect generates hyperthermia while the photodynamic effect produces reactive oxygen species (ROS). Because of this reaction, the arginine residue acts as a donor for nitric oxide generation.

Moreover, this localized release of NO suppresses the expression of heat shock protein 70 (HSP70). Since HSP70 typically helps cancer cells adapt to stress, its inhibition effectively sensitizes the tumor to treatment. Therefore, this mechanism plays a vital role in reversing cervical cancer chemoresistance. Beyond therapy, the Bi-A@SR nanoparticles serve as a diagnostic tool. For instance, the bismuth core provides high-contrast computed tomography (CT) imaging. Additionally, the IR820 enables NIR fluorescence (NIRF) imaging.

This dual-mode approach allows clinicians to monitor drug accumulation in real-time. Moreover, the cRGD peptides ensure that the nanoparticles home directly to the tumor site. As a result, this system minimizes systemic toxicity. By combining imaging-guided delivery with sensitized therapy, this platform represents a significant step forward in personalized oncology.

How do Bi-A@SR nanoparticles target cervical cancer cells?

These nanoparticles use cyclic RGD (cRGD) peptides on their surface. These peptides specifically bind to receptors overexpressed on cervical cancer cells, ensuring the treatment accumulates directly at the tumor site.

Why is Nitric Oxide release important in this therapy?

Nitric Oxide (NO) is released on-demand when the tumor is exposed to NIR light. This NO suppresses Heat Shock Protein 70 (HSP70), which prevents the cancer cells from protecting themselves against the damaging effects of chemotherapy and heat.

What imaging techniques does this platform support?

The platform supports both CT imaging and NIR fluorescence imaging. This integration helps doctors verify exactly where the drug is delivered and how the tumor responds to the treatment in real-time.

Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare provider with any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Abulaizi M et al. Bi-A@SR Nanoparticles Enable Tumor-Localized NO Release to Suppress HSP70 and Reverse Chemoresistance. Adv Healthc Mater. 2026 Jun 06. doi: 10.1002/adhm.71321. PMID: 42251478.
Han J et al. Smart Nanomaterials for Overcoming Cancer Chemoresistance. Front Chem. 2021; 9: 672535.
Zhang Z et al. Nitric Oxide-Releasing Nanoplatforms for Cancer Therapy. Advanced Therapeutics. 2023.